Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. - Wikidata - wikimedia - TriplyDB

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.

http://www.wikidata.org/entity/Q33849560

about

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect T lymphocytes targeting native receptors Evaluation of current cancer immunotherapy: hemato-oncology Adoptive T-cell therapy for Leukemia Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data.Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.Chemoimmunotherapy.Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Genetic modification of T cells Minimal residual disease following allogeneic hematopoietic stem cell transplantation.Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells.Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells Seatbelts in CAR therapy: How Safe Are CARS?Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation.Requirement of CD4 help for induction of CD8 T cell response specific for virally derived h60 Identification and isolation of antigen-specific cytotoxic T lymphocytes with an automated microraft sorting system.Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Cellular therapy following allogeneic stem-cell transplantation.Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Second hematopoietic SCT for leukemia relapsing after myeloablative T cell-depleted transplants does not prolong survival Immunotherapy for pediatric leukemia.Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

P2860

Q26750999-BD6467E4-5EDA-4817-8E4E-9395BE234DA6 Q26775720-FFA00500-82BC-4287-A084-52B9232FB0FA Q26824676-822D5893-0C67-4B75-8A23-8A03F0829C73 Q26826830-C9B02085-7C29-4AA0-9B3B-455269DDC1EE Q26853345-57DBC246-6B6B-45FA-AB38-4F72C901C16A Q27006179-FEF56BCF-6D36-4D43-BC73-3BBF45125ACA Q27006934-EB032C72-3D32-428D-AB6F-96D5142EB45F Q27851694-803A27B5-F731-4680-A795-F3880F8D8231 Q33723635-81407F0C-920D-44F4-A00F-D601915EF847 Q33783183-B3D59822-D3B3-4A4C-9271-F52FD8BCD119 Q33835099-276E2AE4-FFD3-41BB-AE1C-568446696552 Q33931811-87B52B1C-BB03-4D5B-B294-952A3F75CB27 Q33999284-B5AC703D-EE3D-402D-AC72-8D16393B136D Q34018782-68DB0511-0592-49BB-956A-96DD5656532D Q34058792-72FA917C-E13D-46B8-9E98-01785F41502E Q34163218-85C8E0A4-86D5-4A84-8CFA-3029A2CDA9C6 Q34196623-F5BFE7AA-0BF0-4068-B907-CAD698E71339 Q34202277-8E772FED-A2A0-4218-8E44-AC367E52C8AC Q34621730-B8E0C58F-75A0-4EE1-8942-24E0421E28DD Q34644876-8F9ECF95-D84B-465C-9639-DE4DD27842AA Q34667390-A8F73431-F10A-48E2-87E0-47B3334D7D6E Q34792248-E71E430E-9C87-475A-A4FF-37BAFC6ABCD4 Q35000627-1409DC19-3773-44FD-8445-9AFAFA259BB5 Q35585983-BC503348-0AE0-445F-A8AE-B88723BF89D0 Q35651760-136F5963-5FEA-48F2-A32C-D37DFAFBCB14 Q35818365-100587EE-4B34-4FDF-80BC-2376663C2BDB Q35889265-A3D457B9-D46F-4BA2-BDD1-53EEBDBEF6DA Q36113141-9D795E84-24BB-4CA9-BAB8-2EF6059CC474 Q36174792-4F92225B-8351-4709-90D6-F8C4DC5899E6 Q36194803-5C8174DA-ACEE-42C6-8021-08D1AABD8D49 Q36305321-5CF4DBD3-C157-4C7F-A08E-F1D48C3EF050 Q36366557-50D7F6DD-769F-4C05-A7FA-5FAAC4AFD287 Q36612643-E8D583B1-50DA-44DE-86BF-46756710ECA3 Q36662079-7381B82F-FF0A-4C89-84BE-638B5AD259D2 Q36961764-9E2A4B74-C723-4107-AA1B-0FECE68AC569 Q36968163-66914D0B-2E36-4426-B81E-A79188A42723 Q37242561-54B2DB9F-ED2A-414B-9945-BB7863D4C55B Q37263151-B44B62DE-9765-4AEB-BC9B-573838698EC3 Q37390239-496F1901-01EF-4A2A-8B12-2A92D359E72A Q37407181-ABECBAAE-3CE7-435D-B983-AC9F213E7262

P2860

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.

http://www.wikidata.org/entity/Q33849560

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Therapy of relapsed leukemia a ...... r histocompatibility antigens.

@ast

Therapy of relapsed leukemia a ...... r histocompatibility antigens.

@en

type

label

Therapy of relapsed leukemia a ...... r histocompatibility antigens.

@ast

Therapy of relapsed leukemia a ...... r histocompatibility antigens.

@en

prefLabel

Therapy of relapsed leukemia a ...... r histocompatibility antigens.

@ast

Therapy of relapsed leukemia a ...... r histocompatibility antigens.

@en

P1433

Q33849560-A6B190B1-B1A9-4392-B7ED-10F3E279D67F

P1476

Q33849560-9D0F73DA-D032-4CC0-A8F9-EC2466CD22CA

P2093

Q33849560-683D3E21-0F8F-4FAC-AF98-6340196F2A90

Q33849560-68700DC8-AC2B-44FC-B5FC-1D9F75F27468

Q33849560-6CF37AD5-0177-4878-8B32-FBAD5B8491F0

Q33849560-74CEBC4D-D754-4615-A739-9C1751C43E3A

Q33849560-944B6434-4E9A-44CB-80D1-25B5575ABEB5

Q33849560-9581598C-7D02-4622-8EC3-18F0C0401194

Q33849560-9A0C1183-12FB-4E00-975B-1B09FC9C8832

Q33849560-C403DE12-98A5-4156-B2C8-DD3E25902BB5

Q33849560-CA615B34-9867-421E-B28B-5D734C98D9A2

Q33849560-CAFDEB80-4966-4C2A-8F06-F4F56E4C4347

P2860

Q33849560-081ED3EC-C9D7-413A-8D82-37379388176B

Q33849560-3222B591-C658-4086-A977-9175EEDC02D2

Q33849560-34FB6CDD-A969-47EA-9F2D-20F618BA91F0

Q33849560-3F4697C3-E4B7-482B-9BF2-C66A2B5712D2

Q33849560-40B7B5B9-5DD7-4DA8-93BE-81977C5AE786

Q33849560-4393421A-50F9-4EB8-B44A-74E645358BF3

Q33849560-453A4CED-D944-4317-AC89-8067153F79BC

Q33849560-48B8E230-8D90-4464-A29C-6FBBBDD49133

Q33849560-52554233-2D7A-48E7-B4A2-FD57155B7CC0

Q33849560-539F9F89-2CD0-428B-8C08-F4C30161107D

P304

Q33849560-6C0C1F43-3715-4432-97EF-5DBDABABA671

P31

Q33849560-AEB7D453-29B6-4EB9-9DC7-3DA6FE67C926

P356

Q33849560-44E6EC2A-8F77-4F30-8385-35F345242BAC

P407

Q33849560-03767F6D-152F-43BE-884B-115D133D9D27

P433

Q33849560-42A35C44-0313-42CA-8DAB-FD637632EFE6

P478

Q33849560-9EF79CB5-C9F9-41AA-BBF5-7567B9BD566D

P50

Q33849560-ED509873-61F8-4BB7-AB41-2170DD4AD60D

P577

Q33849560-90692FC7-17AC-4331-8159-E94DE65FCD64

P5875

Q33849560-9C7C7082-B7B8-4F6F-924F-3C7EC0FBDF4A

P698

Q33849560-F9C8FD0F-28AB-4655-9A2D-404202A882AF

P921

Q33849560-91F89578-099A-428B-9ECE-CD407A2C66BF

P932

Q33849560-56832862-00B0-469F-852E-691BC1FA0413

P356

BLOOD-2009-10-248997

P1433

P1476

Therapy of relapsed leukemia a ...... r histocompatibility antigens.

@en

P2093

Aiko Matsubara

http://www.w3.org/2001/XMLSchema#string

Colette N Chaney

http://www.w3.org/2001/XMLSchema#string

Edus H Warren

http://www.w3.org/2001/XMLSchema#string

Jeffrey K Mito

http://www.w3.org/2001/XMLSchema#string

Keith R Loeb

http://www.w3.org/2001/XMLSchema#string

Kellie V Rosinski

http://www.w3.org/2001/XMLSchema#string

Kevin K W Koo

http://www.w3.org/2001/XMLSchema#string

Michele L Brown

http://www.w3.org/2001/XMLSchema#string

Nobuharu Fujii

http://www.w3.org/2001/XMLSchema#string

Seishi Ogawa

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Bone marrow transplantation: a review.

The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen.

Molecules and mechanisms of the graft-versus-leukaemia effect.

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells

Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.

Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations

P304

3869-3878

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-10-248997

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Frederick R. Appelbaum

P577

2010-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41013000

http://www.w3.org/2001/XMLSchema#string

P698

20071660

http://www.w3.org/2001/XMLSchema#string

P921

P932

2869557

http://www.w3.org/2001/XMLSchema#string